PCM
ADPT icon

Prelude Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Prelude Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,998
Closed -$422K – 1186
2025
Q4 		$422K Buy
25,998
+7,362
+40% +$120K 0.03% 612
2025
Q3 		$279K Buy
+18,636
New +$227K 0.02% 769
2023
Q4 		– Sell
-13,156
Closed -$71.7K – 1107
2023
Q3 		$71.7K Sell
13,156
-18,648
-59% -$123K ﹤0.01% 1017
2023
Q2 		$213K Sell
31,804
-3,650
-10% -$27.1K 0.01% 821
2023
Q1 		$313K Buy
35,454
+12,776
+56% +$113K 0.02% 630
2022
Q4 		$173K Sell
22,678
-80,138
-78% -$623K 0.01% 1000
2022
Q3 		$732K Buy
102,816
+8,591
+9% +$80.9K 0.03% 516
2022
Q2 		$762K Sell
94,225
-50,957
-35% -$448K 0.02% 622
2022
Q1 		$2.02M Buy
+145,182
New +$2.28M 0.06% 330
2021
Q4 		– Sell
-6,489
Closed -$221K – 1965
2021
Q3 		$221K Sell
6,489
-1,361
-17% -$49.2K 0.01% 1301
2021
Q2 		$321K Sell
7,850
-13,043
-62% -$507K 0.01% 1163
2021
Q1 		$841K Buy
20,893
+15,781
+309% +$854K 0.02% 662
2020
Q4 		$302K Buy
5,112
+3,745
+274% +$193K 0.01% 912
2020
Q3 		$66K Buy
+1,367
New +$57.5K ﹤0.01% 1044
2019
Q4 		– Sell
-143
Closed -$4K – 1876
2019
Q3 		$4K Buy
+143
New +$5.84K ﹤0.01% 1575

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Prelude Capital Management's ADPT Position: Q1 2026 in Review

Prelude Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q1 2026, closing a stake of 25,998 shares — an estimated $422K sold.

Prelude Capital Management first reported a position in ADPT in Q3 2019 and held it in 15 quarters. The position peaked at $2.02M in Q1 2022. 298 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

  • Prelude Capital Management reported no remaining Adaptive Biotechnologies position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 25,998 Adaptive Biotechnologies shares in Q1 2026, an estimated $422K.
  • Prelude Capital Management first reported a position in Adaptive Biotechnologies in Q3 2019 and held it in 15 quarters.
  • Prelude Capital Management's Adaptive Biotechnologies position peaked at $2.02M in Q1 2022.
  • 298 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.